FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid TumorsLeigh Marcus, Steven J. Lemery, Marc R. Theoret et al.|Clinical Cancer Research|2021Cited by 567
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research StatementRandall A. Oyer, Lori J. Pierce, Patricia A. Hurley et al.|Journal of Clinical Oncology|2022Cited by 238
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalitionBob T. Li, Yi‐Long Wu, Bobby Daly et al.|Nature Medicine|2022Cited by 52
Regulatory Considerations for Approval of Chimeric Antigen Receptor T Cell Therapies for Treatment of Hematological MalignanciesMona Elmacken, Lola A. Fashoyin‐Aje, Upendra Mahat et al.|Blood|2024Cited by 2